Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Outlook Therapeutics Inc.

Outlook Therapeutics ( ($OTLK) ) has provided an update. On June 16, 2026, Outlook Therapeutics announced that the U.S. Food and Drug Administratio...

Outlook Therapeutics’ Resubmitted ONS-5010 BLA Accepted by FDA

Outlook Therapeutics ( ($OTLK) ) has provided an announcement. On June 1, 2026, Outlook Therapeutics announced it had resubmitted its Biologics Lic...

Outlook Therapeutics Resubmits FDA Application for ONS-5010

Outlook Therapeutics ( ($OTLK) ) has issued an announcement. On May 28, 2026, Outlook Therapeutics, Inc. entered into a securities purchase agreeme...

Outlook Therapeutics Announces Insider-Backed Direct Stock Offering

Outlook Therapeutics ( ($OTLK) ) just unveiled an update. On May 26, 2026, Outlook Therapeutics said the U.S. FDA granted its appeal after a Formal...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OTLK	$1.58	-4.24%	20.62M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OTLK	$1.58	-4.2%	20.62M
3
4
5
6

OTLK

OTLK

Get Outlook Therapeutics Inc. Data in Excel

Get Outlook Therapeutics Inc. Data in Excel